Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2

Alain H. Rook; Timothy M. Kuzel; Elise A. Olsen

doi:10.1016/S0889-8588(03)00109-6

Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2

Alain H. Rook^*, Timothy M. Kuzel, Elise A. Olsen

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

49 Scopus citations

Abstract

It is well accepted that cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, represent lymphomas that are highly responsive to immune modifying agents. Furthermore, the recent emphasis on the use of cytokine-related therapeutics is based upon the exceedingly important role of the host immune response in effecting progression of disease. In this article we discuss the data that support the importance of the host immune response in the control of progression of CTCL and the role that cytokine therapy has in supporting the host immune response and the effects of this approach to induce regression of skin and systemic disease.

Original language	English (US)
Pages (from-to)	1435-1448
Number of pages	14
Journal	Hematology/Oncology Clinics of North America
Volume	17
Issue number	6
DOIs	https://doi.org/10.1016/S0889-8588(03)00109-6
State	Published - Dec 2003

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0889-8588(03)00109-6

Cite this

@article{9bbb4ffc29344e9d922d83674d50ec8b,

title = "Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2",

abstract = "It is well accepted that cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and S{\'e}zary syndrome, represent lymphomas that are highly responsive to immune modifying agents. Furthermore, the recent emphasis on the use of cytokine-related therapeutics is based upon the exceedingly important role of the host immune response in effecting progression of disease. In this article we discuss the data that support the importance of the host immune response in the control of progression of CTCL and the role that cytokine therapy has in supporting the host immune response and the effects of this approach to induce regression of skin and systemic disease.",

author = "Rook, \{Alain H.\} and Kuzel, \{Timothy M.\} and Olsen, \{Elise A.\}",

year = "2003",

month = dec,

doi = "10.1016/S0889-8588(03)00109-6",

language = "English (US)",

volume = "17",

pages = "1435--1448",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "6",

}

TY - JOUR

T1 - Cytokine therapy of cutaneous T-cell lymphoma

T2 - Interferons, interleukin-12, and interleukin-2

AU - Rook, Alain H.

AU - Kuzel, Timothy M.

AU - Olsen, Elise A.

PY - 2003/12

Y1 - 2003/12

N2 - It is well accepted that cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, represent lymphomas that are highly responsive to immune modifying agents. Furthermore, the recent emphasis on the use of cytokine-related therapeutics is based upon the exceedingly important role of the host immune response in effecting progression of disease. In this article we discuss the data that support the importance of the host immune response in the control of progression of CTCL and the role that cytokine therapy has in supporting the host immune response and the effects of this approach to induce regression of skin and systemic disease.

AB - It is well accepted that cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, represent lymphomas that are highly responsive to immune modifying agents. Furthermore, the recent emphasis on the use of cytokine-related therapeutics is based upon the exceedingly important role of the host immune response in effecting progression of disease. In this article we discuss the data that support the importance of the host immune response in the control of progression of CTCL and the role that cytokine therapy has in supporting the host immune response and the effects of this approach to induce regression of skin and systemic disease.

UR - http://www.scopus.com/inward/record.url?scp=0346996938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346996938&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(03)00109-6

DO - 10.1016/S0889-8588(03)00109-6

M3 - Review article

C2 - 14710894

AN - SCOPUS:0346996938

SN - 0889-8588

VL - 17

SP - 1435

EP - 1448

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 6

ER -

Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this